Cynosure Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Cynosure Group’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,331	Closed	-$449K	–	225
2026 Q1	$449K	Buy	+9,331	New	+$413K	0.06%	100

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Cynosure Group's KNSA Position: Q2 2026 in Review

Cynosure Group sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 9,331 shares — an estimated $449K sold.

Cynosure Group first reported a position in KNSA in Q1 2026 and held it in 1 quarter. The position peaked at $449K in Q1 2026. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Cynosure Group reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Cynosure Group sold 9,331 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $449K.
Cynosure Group first reported a position in Kiniksa Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Cynosure Group's Kiniksa Pharmaceuticals position peaked at $449K in Q1 2026.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Cynosure Group's 13F filing for Q2 2026, filed 5 Aug 2026.